108 related articles for article (PubMed ID: 31736063)
1. Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer.
Kim H; Ju JH; Son S; Shin I
FEBS Lett; 2020 Mar; 594(6):1021-1035. PubMed ID: 31736063
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
3. Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation.
Shimozato O; Waraya M; Nakashima K; Souda H; Takiguchi N; Yamamoto H; Takenobu H; Uehara H; Ikeda E; Matsushita S; Kubo N; Nakagawara A; Ozaki T; Kamijo T
Oncogene; 2015 Apr; 34(15):1949-60. PubMed ID: 24882578
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
Chen J; Shao R; Li F; Monteiro M; Liu JP; Xu ZP; Gu W
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1317-26. PubMed ID: 26399781
[TBL] [Abstract][Full Text] [Related]
6. Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells.
Mao L; Chen Q; Gong K; Xu X; Xie Y; Zhang W; Cao H; Hu T; Hong X; Zhan YY
Oncol Rep; 2018 May; 39(5):2436-2442. PubMed ID: 29565467
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
8. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
Hong SY; Yu FX; Luo Y; Hagen T
Cell Signal; 2016 May; 28(5):377-383. PubMed ID: 26826652
[TBL] [Abstract][Full Text] [Related]
10. Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling.
Tian J; Yuan L
Biomed Pharmacother; 2018 Oct; 106():109-116. PubMed ID: 29957460
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
Matsubara S; Tsukasa K; Kuwahata T; Takao S
Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
[TBL] [Abstract][Full Text] [Related]
12. Deoxyshikonin isolated from
Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
[No Abstract] [Full Text] [Related]
13. ATM inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1-mediated glucose uptake in aggressive cancer cells with sustained activation of Akt.
Harris BRE; Zhang Y; Tao J; Shen R; Zhao X; Cleary MP; Wang T; Yang DQ
FASEB J; 2021 Apr; 35(4):e21264. PubMed ID: 33715230
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
15. CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt-mediated protein synthesis and inhibition of apoptosis.
Mori Y; Takeuchi A; Miyagawa K; Yoda H; Soda H; Nabeya Y; Watanabe N; Ozaki T; Shimozato O
FEBS Open Bio; 2021 May; 11(5):1382-1394. PubMed ID: 33720534
[TBL] [Abstract][Full Text] [Related]
16. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking.
Wieman HL; Wofford JA; Rathmell JC
Mol Biol Cell; 2007 Apr; 18(4):1437-46. PubMed ID: 17301289
[TBL] [Abstract][Full Text] [Related]
17. Effects of CD133 Silencing on Survival and Migration of HT-29 Colorectal Cancer Cells.
Akbari M; Shanehbandi D; Asadi M; Shomali N; Faraji A; Khaze V; Pakdel A; Mokhtarzadeh A; Ebrahimi AA; Shabani A; Bardaran B
Iran J Immunol; 2019 Sep; 16(3):246-257. PubMed ID: 31552833
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation.
Weng CC; Kuo KK; Su HT; Hsiao PJ; Chen YW; Wu DC; Hung WC; Cheng KH
Pancreas; 2016 Mar; 45(3):443-57. PubMed ID: 26646272
[TBL] [Abstract][Full Text] [Related]
19. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profile of cancer stem‑like cells in the SW480 colon adenocarcinoma cell line.
Wang Y; Zhou L; Qing Q; Li Y; Li L; Dong X; Xiao B
Oncol Rep; 2019 Jul; 42(1):386-398. PubMed ID: 31059103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
